Edition:
United Kingdom

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

3.97USD
15 Feb 2019
Change (% chg)

$0.07 (+1.79%)
Prev Close
$3.90
Open
$3.93
Day's High
$3.97
Day's Low
$3.90
Volume
62,274
Avg. Vol
85,623
52-wk High
$17.39
52-wk Low
$3.25

Chart for

About

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson's, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology... (more)

Overall

Beta: --
Market Cap(Mil.): $639.40
Shares Outstanding(Mil.): 56.77
Dividend: --
Yield (%): --

Financials

  ACIU.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -0.69 -- --
ROI: -32.55 8.92 14.45
ROE: -33.72 10.08 15.96

Roche sees 2019 sales, profit rise despite competition from copies

ZURICH Roche expects sales and earnings to rise in 2019 as new drugs more than offset competition from copies of its $20 billion-plus per year trio of cancer medicines Rituxan, Herceptin and Avastin, the Swiss drugmaker said on Thursday.

31 Jan 2019

Roche sees 2019 sales, profit rise despite competition from copies

ZURICH Roche expects sales and earnings to rise in 2019 as new drugs more than offset competition from copies of its $20 billion-plus per year trio of cancer medicines Rituxan, Herceptin and Avastin, the Swiss drugmaker said on Thursday.

31 Jan 2019

UPDATE 2-Roche sees 2019 sales, profit rise despite competition from copies

* Forecasts new medicines to offset competition (Adds details throughout, comment from CEO)

31 Jan 2019

UPDATE 4-Roche, AC Immune drop Alzheimer drug trials after setback

* AC Immune shares plunge 65 percent (Adds AC Immune CEO commment, shares)

30 Jan 2019

Lilly partners with AC Immune for Alzheimer's treatment

U.S. drugmaker Eli Lilly & Co and AC Immune SA have agreed to jointly develop the Swiss biotech's potential treatment for Alzheimer's disease.

12 Dec 2018

UPDATE 1-Lilly partners with AC Immune for Alzheimer's treatment

Dec 12 U.S. drugmaker Eli Lilly & Co and AC Immune SA have agreed to jointly develop the Swiss biotech's potential treatment for Alzheimer's disease.

12 Dec 2018

Lilly partners with AC Immune for Alzheimer's treatment

Dec 12 Eli Lilly & Co and AC Immune SA have agreed to jointly develop a potential treatment for Alzheimer's disease.

12 Dec 2018

BRIEF-AC Immune Says Co's Selling Shareholder May Sell Up To 18 Mln Common Shares

* AC IMMUNE SAYS CO'S SELLING SHAREHOLDER MAY SELL UP TO 18 MILLION COMMON SHARES Source text: (https://bit.ly/2P0dXMm) Further company coverage:

24 Aug 2018

Earnings vs. Estimates